Review



recombinant il 2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems recombinant il 2
    Recombinant Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 903 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/Recombinant+Human+IL-2+Protein/pm42026075-200-17-19
    Average 96 stars, based on 903 article reviews
    recombinant il 2 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial.
    Article Snippet: Xiao-Ying Yao, Zhong-Jiao Lu, Nan Zhao, Li Xie, Chun-Ran Xue, Yi-Shu Wang, Xu-Zhong Pei, Meng-Ze Zhang, Ying Zhang, Wen-Bin Wan, Yan Lin, Ye Deng, Xi-Ying Wang, Yi Chen, He Zhu , Lin-Feng Li, Hui-Ming Xu, Jie Ding, Yi-Fan Wu, Ze Wang, Ya-Ying Song, Kan Wang, Hui-Ying Qiu, Yan Zhou, Yu-Yan Jin, Li-Ping Ni, Jia-Li Yan, Quan Guo, Jia-Hui Xue, Yu-Fang Mei, Bi-Yun Qian3,6, Hao-Jun Yu 1,7,8✉ and Yang-Tai Guan 2✉

    Article Title: Multiplexed high-content imaging uncovers morphological diversity of lymphocyte activation and dysfunction
    Article Snippet: Isolated T cells were cultured in round-bottom 96-well plates or flat-bottom 24-well plates at 1×10 6 cells/mL in StemPro TM 34-SFM (Gibco TM , #10639011) supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. .. Unless specified, recombinant human IL-2 (R&D Systems, #10453-IL) was supplemented every two days (15 ng/mL, 140U/mL). .. T cells were activated using ImmunoCultTM Human aCD3/CD28/CD2 T Cell Activator (STEMCELL Technologies TM , #10970) at 12μL per million cells.

    Article Title: O-GlcNAcylation and low glycolysis underpin Th2 polarization by dendritic cells
    Article Snippet: For Th1/2 polarization, 5.000 DCs that were stimulated for 24h were co-cultured with 20.000 allogenic naïve CD4 T cells in the presence of 20 pg/mL Staphylococcal Enterotoxin B (SEB; #S4881, Sigma) in a cell culture treated flat-bottom 96 well plate. .. After 5-7 days, cells were transferred to a flat-bottom 24 well plate well containing 1 mL of media that was supplemented with 42 IU/mL recombinant human IL-2 (#202-IL, R&D systems). ..

    Article Title: Materials and methods relating to immunogenic epitopes from human papilloma virus
    Article Snippet: Transfection of APCs were done using the Lonza 4D Nucleofector, primary P3 buffer, program E0117 (Lonza, MD, USA) and incubated in BCM-10% human serum, IL-4 without any Anti-Anti. .. Twenty four hours later, on day 1, APCs were washed and incubated with thawed whole HPV+ HNSCC PBMCs at a ratio of 1:2 (200,000 APCs: 400,000 PBMCs) in a 24-well plate in BCM supplemented with 20 U/mL recombinant human IL-2 (R&D Systems, MN, USA), 5 ng/mL IL-7 (R&D Systems, MN, USA). ..

    Article Title: Modeling HIV infection, treatment, rebound, and intervention in human immune organoids
    Article Snippet: PBMCs were thawed, and NK cells were isolated by negative selection using NK-negative selection kits (Miltenyi Biotec, #130-092-657). .. NK cells were cultured overnight in R10 medium (RPMI 1640, with 10% FBS, 1% L-glutamine, 1% sodium pyruvate, and 1% PSA Penicillin/Streptomycin/ Actinomycin) supplemented with 300 IU/ml recombinant human IL-2 (R&D Systems) for 18hrs +/- 2hrs. ..

    Article Title: Loss of Vpr-driven TRAIL-R2 expression protects HIV-infected cells from non-canonical NK cell TRAIL attack
    Article Snippet: Prior to isolating CD4 + T cells, a non-TC treated sterile 24-well plate (Corning, Inc., Cat.#CLS3738) was coated with 400μL per well of 2μg/mL anti-CD3 antibody (Biolegend, Cat.#317326), diluted in Coating Buffer for at least 2hrs at 37°C, or overnight at 4°C. .. Before plating cells, each well was washed twice with sterile PBS, then given 0.4mL R10 media containing 10ng/mL recombinant human IL-2 (R10/IL-2 Media: IL-2 from R&D Systems, Cat.#202-IL-500). .. CD4 + T cells were isolated from PBMC via negative selection (Stemcell Technologies, Cat.#17952), according to the manufacturer’s instructions.

    Article Title: Selective Immune Silencing by Targeted TGF-β Agonists
    Article Snippet: .. For human in vitro cultures, T cells were plated at 0.75 × 10 6 cells/mL in flat-bottom 12-well plates coated overnight with 5 μg/mL InVivoMAb anti-human CD3 (BE0001, Bio X Cell) and 2.5 μg/mL InVivoMAb anti-human CD28 (BE0248, Bio X Cell) in the presence of 10 ng/mL recombinant human IL-2 (202-IL, R&D Systems) for 3 days. ..

    Article Title: Materials and methods relating to immunogenic epitopes from human papilloma virus
    Article Snippet: APCs were either peptide pulsed with HPV16-epitopes, or transfected with whole HPV-antigen encoded in mammalian expression plasmid pCDNA3.2 (Invitrogen, CA, USA). .. APCs were washed and incubated with thawed whole HPV+ HNSCC PBMCs at a ratio of 1:2 (200,000 APCs: 400,000 PBMCs) supplemented with 20 U/mL recombinant human IL-2 (R&D Systems, MN, USA), 5 ng/mL IL-7 (R&D Systems, MN, USA). ..

    Activation Assay:

    Article Title: Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial.
    Article Snippet: Xiao-Ying Yao, Zhong-Jiao Lu, Nan Zhao, Li Xie, Chun-Ran Xue, Yi-Shu Wang, Xu-Zhong Pei, Meng-Ze Zhang, Ying Zhang, Wen-Bin Wan, Yan Lin, Ye Deng, Xi-Ying Wang, Yi Chen, He Zhu , Lin-Feng Li, Hui-Ming Xu, Jie Ding, Yi-Fan Wu, Ze Wang, Ya-Ying Song, Kan Wang, Hui-Ying Qiu, Yan Zhou, Yu-Yan Jin, Li-Ping Ni, Jia-Li Yan, Quan Guo, Jia-Hui Xue, Yu-Fang Mei, Bi-Yun Qian3,6, Hao-Jun Yu 1,7,8✉ and Yang-Tai Guan 2✉

    Incubation:

    Article Title: Materials and methods relating to immunogenic epitopes from human papilloma virus
    Article Snippet: Transfection of APCs were done using the Lonza 4D Nucleofector, primary P3 buffer, program E0117 (Lonza, MD, USA) and incubated in BCM-10% human serum, IL-4 without any Anti-Anti. .. Twenty four hours later, on day 1, APCs were washed and incubated with thawed whole HPV+ HNSCC PBMCs at a ratio of 1:2 (200,000 APCs: 400,000 PBMCs) in a 24-well plate in BCM supplemented with 20 U/mL recombinant human IL-2 (R&D Systems, MN, USA), 5 ng/mL IL-7 (R&D Systems, MN, USA). ..

    Article Title: Materials and methods relating to immunogenic epitopes from human papilloma virus
    Article Snippet: APCs were either peptide pulsed with HPV16-epitopes, or transfected with whole HPV-antigen encoded in mammalian expression plasmid pCDNA3.2 (Invitrogen, CA, USA). .. APCs were washed and incubated with thawed whole HPV+ HNSCC PBMCs at a ratio of 1:2 (200,000 APCs: 400,000 PBMCs) supplemented with 20 U/mL recombinant human IL-2 (R&D Systems, MN, USA), 5 ng/mL IL-7 (R&D Systems, MN, USA). ..

    Cell Culture:

    Article Title: Modeling HIV infection, treatment, rebound, and intervention in human immune organoids
    Article Snippet: PBMCs were thawed, and NK cells were isolated by negative selection using NK-negative selection kits (Miltenyi Biotec, #130-092-657). .. NK cells were cultured overnight in R10 medium (RPMI 1640, with 10% FBS, 1% L-glutamine, 1% sodium pyruvate, and 1% PSA Penicillin/Streptomycin/ Actinomycin) supplemented with 300 IU/ml recombinant human IL-2 (R&D Systems) for 18hrs +/- 2hrs. ..

    Sterility:

    Article Title: Loss of Vpr-driven TRAIL-R2 expression protects HIV-infected cells from non-canonical NK cell TRAIL attack
    Article Snippet: Prior to isolating CD4 + T cells, a non-TC treated sterile 24-well plate (Corning, Inc., Cat.#CLS3738) was coated with 400μL per well of 2μg/mL anti-CD3 antibody (Biolegend, Cat.#317326), diluted in Coating Buffer for at least 2hrs at 37°C, or overnight at 4°C. .. Before plating cells, each well was washed twice with sterile PBS, then given 0.4mL R10 media containing 10ng/mL recombinant human IL-2 (R10/IL-2 Media: IL-2 from R&D Systems, Cat.#202-IL-500). .. CD4 + T cells were isolated from PBMC via negative selection (Stemcell Technologies, Cat.#17952), according to the manufacturer’s instructions.

    In Vitro:

    Article Title: Selective Immune Silencing by Targeted TGF-β Agonists
    Article Snippet: .. For human in vitro cultures, T cells were plated at 0.75 × 10 6 cells/mL in flat-bottom 12-well plates coated overnight with 5 μg/mL InVivoMAb anti-human CD3 (BE0001, Bio X Cell) and 2.5 μg/mL InVivoMAb anti-human CD28 (BE0248, Bio X Cell) in the presence of 10 ng/mL recombinant human IL-2 (202-IL, R&D Systems) for 3 days. ..



    Similar Products

    93
    MedChemExpress recombinant human il 2 protein
    Recombinant Human Il 2 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/IL-2%2C+Human/pmc13389675-136-27-31
    Average 93 stars, based on 1 article reviews
    recombinant human il 2 protein - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec recombinant human il 2
    Recombinant Human Il 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/Human+IL-2+IS%2C+research+grade/pm42447864-743-33-36
    Average 96 stars, based on 1 article reviews
    recombinant human il 2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec medium
    Medium, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/MACS+GMP+Recombinant+Human+IL-2/us12668640-299-2-10
    Average 94 stars, based on 1 article reviews
    medium - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    86
    Novoprotein recombinant human il 2
    Recombinant Human Il 2, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/2+human+il+recombinant/pm42284413-250-60-66
    Average 86 stars, based on 1 article reviews
    recombinant human il 2 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec recombinant il 2 ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Il 2 Ril 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/Human+IL-2+IS%2C+research+grade/med_rxiv__64898__2026__05__30__26354518-212-13-17
    Average 96 stars, based on 1 article reviews
    recombinant il 2 ril 2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    Procell Inc recombinant human il 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Human Il 2, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/epidermal+factor+growth/pm42168330-416-0-5
    Average 86 stars, based on 1 article reviews
    recombinant human il 2 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Novartis human recombinant il 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Human Recombinant Il 2, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/2+human+il/pm42074105-143-0-4
    Average 86 stars, based on 1 article reviews
    human recombinant il 2 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    96
    R&D Systems recombinant il 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/Recombinant+Human+IL-2+Protein/pm42026075-200-17-19
    Average 96 stars, based on 1 article reviews
    recombinant il 2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    R&D Systems iu il 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Iu Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+il+2/Recombinant+Human+IL-2+Protein/pmc13103101-251-48-50
    Average 96 stars, based on 1 article reviews
    iu il 2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    Plasma level IL-2 in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.

    Journal: medRxiv

    Article Title: Targeting PTP1B and DUSP4 phosphatases to Boost Tregs: A Novel Therapy for Polyendocrine Metabolic Ovarian Syndrome (PMOS) Immune Dysfunction

    doi: 10.64898/2026.05.30.26354518

    Figure Lengend Snippet: Plasma level IL-2 in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.

    Article Snippet: After 24 hours of siRNA treatment, the cells were stimulated with 300IU of recombinant IL-2 (rIL-2) (#130-097-743, Miltenyi Biotech, Germany).

    Techniques: Clinical Proteomics, Control, Gene Expression

    FACS analysis showed an increase of CD4 +ve CD25 +ve CD127 low/- Treg population after PTP1B and DUSP4 (MKP-2) siRNA-based knockdown in PBMCs of PMOS (n=12) subjects. A: bar graph representation showing the gene expression of PTP1B and DUSP4 across the PTP1B, DUSP4, and both silenced PBMCs. B: Dot plot and histogram representation of gating strategy with P1 shows lymphocyte population, P2 shows CD4-FITC +ve population, P3 shows CD25-PE Cy7 +ve population and P4 shows CD127 low/- Treg population. Gating is based on histogram of unstained and stained population (FITC, PE Cy7 and Alexa Fluor 647 respectively). C: Dot plot representation of CD4-FITC +ve CD25-PECy7 +ve CD127-Alexa Fluor 647 low/- (P4) Treg population of all treatment conditions including; untreated, IL-2 treated, control siRNA silenced, control siRNA silenced with IL-2, PTP1B siRNA silenced without IL-2 and with IL-2, DUSP4 siRNA silenced without IL-2 and with IL-2, and PTP1B+DUSP4 siRNA silenced without IL-2 and with IL-2. D: Dot and truncated violin plot representation of the percentage of CD4 +ve CD25 +ve CD127 low/- Treg population in lymphocyte events across all the treatments. Each dot represents an individual subject. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were considered as statistically significant.

    Journal: medRxiv

    Article Title: Targeting PTP1B and DUSP4 phosphatases to Boost Tregs: A Novel Therapy for Polyendocrine Metabolic Ovarian Syndrome (PMOS) Immune Dysfunction

    doi: 10.64898/2026.05.30.26354518

    Figure Lengend Snippet: FACS analysis showed an increase of CD4 +ve CD25 +ve CD127 low/- Treg population after PTP1B and DUSP4 (MKP-2) siRNA-based knockdown in PBMCs of PMOS (n=12) subjects. A: bar graph representation showing the gene expression of PTP1B and DUSP4 across the PTP1B, DUSP4, and both silenced PBMCs. B: Dot plot and histogram representation of gating strategy with P1 shows lymphocyte population, P2 shows CD4-FITC +ve population, P3 shows CD25-PE Cy7 +ve population and P4 shows CD127 low/- Treg population. Gating is based on histogram of unstained and stained population (FITC, PE Cy7 and Alexa Fluor 647 respectively). C: Dot plot representation of CD4-FITC +ve CD25-PECy7 +ve CD127-Alexa Fluor 647 low/- (P4) Treg population of all treatment conditions including; untreated, IL-2 treated, control siRNA silenced, control siRNA silenced with IL-2, PTP1B siRNA silenced without IL-2 and with IL-2, DUSP4 siRNA silenced without IL-2 and with IL-2, and PTP1B+DUSP4 siRNA silenced without IL-2 and with IL-2. D: Dot and truncated violin plot representation of the percentage of CD4 +ve CD25 +ve CD127 low/- Treg population in lymphocyte events across all the treatments. Each dot represents an individual subject. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were considered as statistically significant.

    Article Snippet: After 24 hours of siRNA treatment, the cells were stimulated with 300IU of recombinant IL-2 (rIL-2) (#130-097-743, Miltenyi Biotech, Germany).

    Techniques: Knockdown, Gene Expression, Staining, Control